Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Enhancing Lumbar Spinal Fusion Using Hypoxia Preconditioned Culture-Expanded Adipose-Derived Mesenchymal Stem Cells: Evidence From a Rat Posterolateral Lumbar Spinal Fusion Model.

Perdomo-Pantoja A., Shafi M., Sarkar N., Rajkovic C., Holmes C., Cottrill E.

Randomized Controlled Trial on Back & Spine, published in Neurosurgery (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Neurosurgery (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42017849
DOI
10.1227/neu.0000000000004055

Abstract (original English)

Background and objectives Adipose-derived stem cells (ADSCs) offer a practical alternative to bone marrow-derived stem cells. They are often limited by poor cell survival following implantation into the hypoxic environment surrounding the fusion site. Dimethyloxalylglycine (DMOG), a stabilizer of hypoxia-inducible factor-1α, has been shown to boost both osteogenic and angiogenic functions of mesenchymal stem cells under low oxygen conditions. In this study, we investigated whether preconditioning ADSCs with DMOG and hypoxia could improve their bone-forming capacity and stimulate vascularization. Methods ADSCs were harvested from the inguinal fat pads of Lewis rats aged 6-8 weeks. After culture expansion, cells at passage 1 (P1) (80% confluency) were preconditioned with DMOG (1 ng) for 24 hours. Cells at passage 2 (P2) were then seeded onto Vitoss scaffolds at a dose of 2 × 106 cells per scaffold for implantation. Rats underwent L4-L5 posterolateral spinal fusion and were randomly assigned to 1 of 2 groups: (1) Vitoss containing DMOG-preconditioned P2 ADSCs or (2) Vitoss containing nonpreconditioned P2 ADSCs. Fusion outcomes were evaluated 8 weeks postoperatively using manual palpation (graded as 0 = nonfused, 1 = partial fusion, and, 2 = fused), micro-computed tomography (micro-CT) imaging (0 = nonfused; 1 = unilateral fusion; 2 = bilateral fusion), and histology. Results Micro

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research